Biomira submits Tru-Scint in Canada
This article was originally published in Clinica
Biomira has made a New Drug Submission to the Canadian Health Protection Branch for its Tru-Scint AD imaging agent. The submission covers the detection of recurrent breast cancer and primary, residual or recurrent ovarian cancer. The Canadian agency has indicated it will give the technetium-99m-labelled monoclonal antibody priority evaluation status, since the active substance may provide more effective diagnosis of serious and life threatening diseases than currently used protocols.
You may also be interested in...
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.